THE POTENT AND SELECTIVE B3-ADRENOCEPTOR AGONIST MIRABEGRON IMPROVES PATIENT-REPORTED OUTCOMES IN OVERACTIVE BLADDER-RESULTS FROM TWO PHASE III STUDIES

被引：0
|
作者：
Nitti, V [1 ]
Herschorn, S. [2 ]
Auerbach, S. [3 ]
Khullar, V [4 ]
Amarenco, G. [5 ]
Blauwet, M. B. [6 ]
Boerrigter, P. [7 ]
Hakimi, Z. [8 ]
Siddiqui, E. [9 ]
Martin, N. [10 ]
机构：
[1] NYU Langone Med Ctr, Dept Urol, New York, NY USA
[2] Univ Toronto, Div Urol, Toronto, ON, Canada
[3] Hoag Mem Hosp, Newport Beach, CA USA
[4] Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, Urogynaecol Dept, London, England
[5] Hop Rothschild, Assistance Publ Hop Paris, Dept Neurol Rehabil, Urodynam & Neurophysiol Lab, F-75571 Paris, France
[6] Astellas Pharma Global Dev Inc, Biostat, Deerfield, IL USA
[7] Astellas Pharma Global Dev EU, Leiderdorp, Netherlands
[8] Astellas Pharma Europe, Leiderdorp, Netherlands
[9] Astellas Pharma Europe Ltd, Staines, Middx, England
[10] Astellas Sci & Med Affairs Inc, Deerfield, IL USA
来源：
NEUROUROLOGY AND URODYNAMICS | 2012年 / 31卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
68
引用
收藏
页码：813 / 815
页数：3
相关论文
共 50 条
  • [31] Efficacy of the β3-adrenoceptor Agonist Mirabegron for the Treatment of Overactive Bladder by Severity of Incontinence at Baseline: A Post Hoc Analysis of Pooled Data from Three Randomised Phase 3 Trials
    Chapple, Christopher
    Khullar, Vik
    Nitti, Victor W.
    Frankel, Jeffrey
    Herschorn, Sender
    Kaper, Mathilde
    Blauwet, Mary Beth
    Siddiqui, Emad
    EUROPEAN UROLOGY, 2015, 67 (01) : 11 - 14
  • [32] Improved Patient-Reported Outcomes in Psoriatic Arthritis Patients Treated with Abatacept: Results from a Phase III Trial
    Strand, Vibeke
    Alemao, E.
    Lehman, T.
    Johnsen, A.
    Banerjee, S.
    Ahmad, H. A.
    Mease, Philip J.
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [33] IMPROVED PATIENT-REPORTED OUTCOMES IN PSORIATIC ARTHRITIS PATIENTS TREATED WITH ABATACEPT: RESULTS FROM A PHASE III TRIAL
    Strand, V.
    Alemao, E.
    Lehman, T.
    Johnsen, A.
    Banerjee, S.
    Ahmad, H.
    Mease, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 687 - 687
  • [34] EFFECTS OF THE β3-ADRENOCEPTOR AGONIST, MIRABEGRON, ON QUALITY OF LIFE IN OLDER PATIENTS WITH OVERACTIVE BLADDER: A POST-HOC ANALYSIS OF POOLED DATA FROM 3 RANDOMISED PHASE 3 TRIALS
    Wagg, Adrian
    Nitti, Victor
    Kelleher, Con
    Auerbach, Stephen
    Blauwet, Mary Beth
    Siddiqui, Emad
    JOURNAL OF UROLOGY, 2014, 191 (04): : E339 - E339
  • [35] Phase III, randomised, double-blind, placebo-controlled study of the 3-adrenoceptor agonist mirabegron, 50mg once daily, in Japanese patients with overactive bladder
    Yamaguchi, Osamu
    Marui, Eiji
    Kakizaki, Hidehiro
    Homma, Yukio
    Igawa, Yasuhiko
    Takeda, Masayuki
    Nishizawa, Osamu
    Gotoh, Momokazu
    Yoshida, Masaki
    Yokoyama, Osamu
    Seki, Narihito
    Ikeda, Yasushi
    Ohkawa, Sumito
    BJU INTERNATIONAL, 2014, 113 (06) : 951 - 960
  • [36] Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
    Thaci, D.
    Kimball, A.
    Foley, P.
    Poulin, Y.
    Levi, E.
    Chen, R.
    Feldman, S. R.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 498 - 506
  • [37] The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
    Castro-Diaz, D.
    Chapple, C. R.
    Hakimi, Z.
    Blauwet, M. B.
    Delgado-Herrera, L.
    Lau, W.
    Mujais, S.
    QUALITY OF LIFE RESEARCH, 2015, 24 (07) : 1719 - 1727
  • [38] The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials
    D. Castro-Diaz
    C. R. Chapple
    Z. Hakimi
    M. B. Blauwet
    L. Delgado-Herrera
    W. Lau
    S. Mujais
    Quality of Life Research, 2015, 24 : 1719 - 1727
  • [39] NETAKIMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL (PATERA)
    Korotaeva, T.
    Gaydukova, I.
    Mazurov, V.
    Samtsov, A.
    Khayrutdinov, V.
    Bakulev, A.
    Kokhan, M.
    Kundzer, A.
    Soroka, N.
    Dokukina, E.
    Eremeeva, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1691 - 1692
  • [40] Pharmacokinetic Properties of Mirabegron, a β3-Adrenoceptor Agonist: Results From Two Phase I, Randomized, Multiple-Dose Studies in Healthy Young and Elderly Men and Women
    Krauwinkel, Walter
    van Dijk, Jan
    Schaddelee, Marloes
    Eltink, Charlotte
    Meijer, John
    Strabach, Gregory
    van Marle, Sjoerd
    Kerbusch, Virginie
    van Gelderen, Marcel
    CLINICAL THERAPEUTICS, 2012, 34 (10) : 2144 - 2160
12345